Tags

Type your tag names separated by a space and hit enter

Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
Semin Thromb Hemost. 2008 Apr; 34(3):256-66.ST

Abstract

This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to beta2 glycoprotein I (beta2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be "pathogenic." A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be "pathogenic" but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid-associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.

Authors+Show Affiliations

Division of Immunology, The School of Pathology, University of the Witwatersrand, The Netcare Rosebank Hospital, Rosebank, Johannesburg, South Africa. ashron@icon.co.zaNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18720305

Citation

Asherson, Ronald A., et al. "Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Clinical Significance and Treatment." Seminars in Thrombosis and Hemostasis, vol. 34, no. 3, 2008, pp. 256-66.
Asherson RA, Cervera R, Merrill JT, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008;34(3):256-66.
Asherson, R. A., Cervera, R., Merrill, J. T., & Erkan, D. (2008). Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Seminars in Thrombosis and Hemostasis, 34(3), 256-66. https://doi.org/10.1055/s-0028-1082269
Asherson RA, et al. Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Clinical Significance and Treatment. Semin Thromb Hemost. 2008;34(3):256-66. PubMed PMID: 18720305.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. AU - Asherson,Ronald A, AU - Cervera,Ricard, AU - Merrill,Joan T, AU - Erkan,Doruk, PY - 2008/8/23/pubmed PY - 2008/12/17/medline PY - 2008/8/23/entrez SP - 256 EP - 66 JF - Seminars in thrombosis and hemostasis JO - Semin Thromb Hemost VL - 34 IS - 3 N2 - This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to beta2 glycoprotein I (beta2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be "pathogenic." A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be "pathogenic" but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid-associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed. SN - 0094-6176 UR - https://www.unboundmedicine.com/medline/citation/18720305/Antiphospholipid_antibodies_and_the_antiphospholipid_syndrome:_clinical_significance_and_treatment_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0028-1082269 DB - PRIME DP - Unbound Medicine ER -